Clinical trial · Interventional
An HPV Vaccine Provider Intervention in Safety Net Clinics
Development of an HPV Vaccine and Cervical Cancer Screening Provider Intervention
NCT02808832CI-TRIAL-00023876completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to develop, deliver and evaluate a provider intervention for mothers and their children to encourage receipt of the human papillomavirus (HPV) vaccine in the children and appropriate cervical cancer screening in the mothers.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Human Papillomavirus | — | UNRESOLVED | — |
| Uterine Cervical Neoplasms | Cervical Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Educational materials | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Educational materials
- description
- 5-minute video and information sheet with a list of suggested questions to ask the provider
- interventionNames
- Behavioral: Educational materials
- type
- NO_INTERVENTION
- label
- Usual care
- description
- Usual care
Primary outcomes (1)
- measure
- Number of children participants who completed the 3-dose HPV vaccine series
- timeFrame
- 12 months
- description
- Although completion of the 3-dose HPV vaccine series is recommended within 6 months, the investigators measured completion within 12 months.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 9 Years
Show eligibility criteria text
Inclusion Criteria: * Being seen as a pediatric patient at a study clinic on the day of enrollment * Self-identified African American or Hispanic * Aged 9-18 years (mother accompanying child to clinic visit had no age limit) * Had received no doses of HPV vaccine or received one shot and was overdue for the second dose (three or more months after the first dose was given) prior to the clinic visit Exclusion Criteria: * Already having received two or more doses of HPV vaccine * Mother or female guardian (referred to as "mother" henceforth) not accompanying the child * Plans to move away from the clinic catchment area within the next 12 months * Not completing the baseline assessment prior to entering the exam room * Mother not providing or unable to give consent * Child not giving assent.
References
Publications (1)
- DERIVEDSanderson M, Canedo JR, Khabele D, Fadden MK, Harris C, Beard K, Burress M, Pinkerton H, Jackson C, Mayo-Gamble T, Hargreaves MK, Hull PC. Pragmatic trial of an intervention to increase human papillomavirus vaccination in safety-net clinics. BMC Public Health. 2017 Feb 2;17(1):158. doi: 10.1186/s12889-017-4094-1. PMID 28153042